Talquetamab in Patients With RRMM: Key Takeaways From MontumenTAL-1
Ajai Chari, MD, details the accelerated FDA approval of talquetamab based on data from the MonumenTAL-1 study showing positive response rates in patients with advanced multiple myeloma. The study highlighted the latest efficacy results of every-two-week dosing, which demonstrated an advantageous option for patients treated with four or more lines of therapy and triple class exposure.
EP: 1.Case Presentation: A 71-Year-Old Woman with Relapsed/Refractory Multiple Myeloma (RRMM)
EP: 2.Available Treatments for Patients With RRMM After 4+ Prior Lines of Therapy
EP: 3.Talquetamab in Patients With RRMM: Key Takeaways From MontumenTAL-1
EP: 4.Emerging Treatments for Patients With RRMM: Data From CARTITUDE-1
EP: 5.Toxicity Management for Emerging Bispecifics in Patients With RRMM
EP: 6.The Future of Patient Care in RRMM
DREAMM-8 Trial Demonstrates Benefits of Belantamab Mafodotin
October 3rd 2024Belantamab mafodotin plus pomalidomide and dexamethasone showed significant progression-free survival benefits and maintained quality of life in patients with relapsed/refractory multiple myeloma, as demonstrated in the DREAMM-8 trial.
Read More
Single CAR-T Infusion Shows Deep and Durable Responses in Relapsed Myeloma
October 2nd 2024A single infusion of the autologous GPRC5D-targeted CAR T-cell therapy BMS-986393 led to high response rates in patients with relapsed/refractory multiple myeloma who received between 1 and 3 prior lines of therapy.
Read More
